Gestational Alloimmune Liver Disease (GALD)

Overview

Gestational Alloimmune Liver Disease (GALD) is a rare but serious cause of neonatal acute liver failure (NALF). It is still referred to as GALD, often in the context of GALD-associated neonatal hemochromatosis (GALD-NH) due to its characteristic iron deposition pattern.

Pathophysiology

Maternal IgG antibodies cross the placenta and target fetal liver antigens.
Complement cascade activation, especially C5b-9, leads to hepatocyte destruction.
Results in liver fibrosis and extrahepatic siderosis (iron deposition in other organs).

Clinical Manifestations

Neonatal liver failure: coagulopathy, hypoglycemia, elevated ferritin and alpha-fetoprotein.
Ascites, jaundice, edema, bleeding, and sometimes hydrops fetalis.
Encephalopathy is typically absent in neonates.

Diagnosis

Clinical suspicion in neonates with unexplained liver failure.
MRI or buccal biopsy to detect extrahepatic siderosis.
Liver biopsy with C5b-9 staining (supportive but not required).
Rule out mimics like HLH, mitochondrial disorders, and infections.

Lab Findings in GALD

Typical Laboratory Findings in Gestational Alloimmune Liver Disease (GALD)

Comprehensive Lab Findings
Test	Finding	Explanation
INR / PT / aPTT	Elevated (INR often > 3)	Severe coagulopathy due to impaired clotting factor synthesis
Blood Glucose	Low	Hypoglycemia from impaired gluconeogenesis and glycogen storage
AST / ALT	Mildly elevated	Modest transaminase elevation despite severe liver injury
Ferritin	Markedly elevated (>800 ng/mL)	Reflects inflammation and iron overload
Alpha-fetoprotein (AFP)	Extremely high (>100,000 ng/mL)	Due to fetal liver regeneration attempts
Succinylacetone	Normal	Helps rule out tyrosinemia type I
Albumin	Low	Impaired hepatic protein synthesis
Bilirubin	May be elevated	Variable; not always prominent
Platelet count	Normal or low	Possible thrombocytopenia from liver dysfunction

Liver Function and Injury

Coagulopathy: Elevated INR and PT/aPTT due to impaired clotting factor synthesis; often severe (INR > 3).
Hypoglycemia: Resulting from impaired gluconeogenesis and glycogen storage.
Mildly elevated transaminases: AST and ALT may be modestly raised despite severe liver injury.

Inflammatory and Iron Markers

Ferritin: Markedly elevated (>800 ng/mL), reflecting inflammation and iron overload.
Alpha-fetoprotein (AFP): Extremely high (>100,000 ng/mL), due to fetal liver regeneration attempts.

Other Findings

Succinylacetone: Normal — helps rule out tyrosinemia type I.

Albumin: Low, due to impaired synthetic function.

Bilirubin: May be elevated but not always prominent.

Platelets: Normal or low — possible thrombocytopenia from liver dysfunction.

Treatment

Double-volume exchange transfusion (DVET) to remove maternal antibodies.
High-dose IVIG to block complement activation.
Avoid maternal breast milk during acute phase.
Prenatal IVIG for mothers with prior affected pregnancies to prevent recurrence.

Prognosis

Without treatment: poor prognosis (~17% survival without transplant).
With DVET + IVIG: up to 75% survival without liver transplant.
Liver transplant may be needed in severe cases.
Recurrence risk in future pregnancies >90%, but preventable with prenatal IVIG.